Syndax Pharmaceuticals (SNDX) Revenue & Revenue Breakdown
Syndax Pharmaceuticals Revenue Highlights
Latest Revenue (Q)
$3.50M
Syndax Pharmaceuticals Revenue by Period
Syndax Pharmaceuticals Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | - | 100.00% |
2022-12-31 | - | -100.00% |
2021-12-31 | $139.71M | 9109.56% |
2020-12-31 | $1.52M | - |
2019-12-31 | $1.52M | - |
2018-12-31 | $1.52M | -28.04% |
2017-12-31 | $2.11M | 72.79% |
2016-12-31 | $1.22M | 94.58% |
2015-12-31 | $627.00K | 100.00% |
2014-12-31 | - | 100.00% |
2013-12-31 | - | 100.00% |
2012-12-31 | - | - |
Syndax Pharmaceuticals Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-06-30 | $3.50M | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $536.00K | 100.00% |
2023-09-30 | - | 100.00% |
2023-06-30 | - | 100.00% |
2023-03-31 | - | 100.00% |
2022-12-31 | - | 100.00% |
2022-09-30 | - | 100.00% |
2022-06-30 | - | 100.00% |
2022-03-31 | - | -100.00% |
2021-12-31 | $126.58M | 922.84% |
2021-09-30 | $12.38M | 3165.17% |
2021-06-30 | $379.00K | - |
2021-03-31 | $379.00K | -0.26% |
2020-12-31 | $380.00K | 0.26% |
2020-09-30 | $379.00K | - |
2020-06-30 | $379.00K | - |
2020-03-31 | $379.00K | -0.26% |
2019-12-31 | $380.00K | 0.26% |
2019-09-30 | $379.00K | - |
2019-06-30 | $379.00K | - |
2019-03-31 | $379.00K | -0.26% |
2018-12-31 | $380.00K | 0.26% |
2018-09-30 | $379.00K | - |
2018-06-30 | $379.00K | - |
2018-03-31 | $379.00K | -68.23% |
2017-12-31 | $1.19M | 291.15% |
2017-09-30 | $305.00K | - |
2017-06-30 | $305.00K | - |
2017-03-31 | $305.00K | - |
2016-12-31 | $305.00K | - |
2016-09-30 | $305.00K | - |
2016-06-30 | $305.00K | - |
2016-03-31 | $305.00K | - |
2015-12-31 | $305.00K | - |
2015-09-30 | $305.00K | 1694.12% |
2015-06-30 | $17.00K | 100.00% |
2015-03-31 | - | 100.00% |
2014-12-31 | - | 100.00% |
2014-09-30 | - | 100.00% |
2014-06-30 | - | 100.00% |
2014-03-31 | - | 100.00% |
2013-12-31 | - | 100.00% |
2013-09-30 | - | 100.00% |
2013-06-30 | - | 100.00% |
2013-03-31 | - | - |
Syndax Pharmaceuticals Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
STRO | Sutro Biopharma | $153.73M | $13.01M |
MRUS | Merus | $43.95M | $7.33M |
MRSN | Mersana Therapeutics | $36.85M | $2.29M |
RVMD | Revolution Medicines, Inc. Warrant | $11.58M | - |
CYTK | Cytokinetics | $7.53M | $249.00K |
PLRX | Pliant Therapeutics | $1.58M | - |
KRTX | Karuna Therapeutics | $654.00K | - |
VRDN | Viridian Therapeutics | $314.00K | $72.00K |
KROS | Keros Therapeutics | $151.00K | $83.00K |
CGEM | Cullinan Oncology | - | - |
PCVX | Vaxcyte | - | - |
COGT | Cogent Biosciences | - | - |
AVTE | Aerovate Therapeutics | - | - |
DICE | DICE Therapeutics | - | - |
INZY | Inozyme Pharma | - | - |
DYN | Dyne Therapeutics | - | - |
REPL | Replimune Group | - | - |
SNDX | Syndax Pharmaceuticals | - | $3.50M |
MLYS | Mineralys Therapeutics | - | - |
LRMR | Larimar Therapeutics | - | - |
KALV | KalVista Pharmaceuticals | - | - |
EWTX | Edgewise Therapeutics | - | - |
SNDX Revenue FAQ
What is Syndax Pharmaceuticals’s yearly revenue?
Syndax Pharmaceuticals's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing a decrease of -100.00% compared to 2021. SNDX's yearly revenue for 2021 was $139.71M, representing an increase of 9109.56% compared to 2020.
What is Syndax Pharmaceuticals’s quarterly revenue?
Syndax Pharmaceuticals's quarterly revenue for Q2 2024 was $3.5M, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). SNDX's quarterly revenue for Q4 2023 was $536K, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Syndax Pharmaceuticals’s revenue growth rate?
Syndax Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -100.00%.